Marisa Wexler, MS, senior science writer —

A committee of the European Medicines Agency has recommended approving Tavneos (avacopan) as an add-on therapy for adults with severe, active microscopic polyangiitis (MPA) or granulomatosis with polyangiitis (GPA), the two most common types of ANCA-associated vasculitis. This recommendation from the Committee for Medicinal Products for Human Use…

A new classification system, based on the underlying cause of disease, may be necessary to better understand ANCA-associated vasculitis (AAV) and other disorders characterized by inflammation in the blood vessels. That’s according to a team led by scientists at Aarhus University, in Denmark, who published their idea for the…

A reduced dosage of rituximab maintenance therapy may be effective at preventing relapses among people with ANCA-associated vasculitis (AAV), a new study reports. Specifically, the researchers said 500 mg infusions every six months “appear to be an effective and safe option” for maintaining AAV remission. “This study provides real-world…

Treatment with ChemoCentryx’s investigational therapy avacopan can improve kidney function in people with ANCA-associated vasculitis to a greater extent than steroids, especially among individuals with advanced kidney disease, clinical trial data show. The data were presented at the annual meeting of the European Renal Association –…

Eurordis opened a campaign, called Rare 2030 Action, that is seeking to establish a European action plan for rare diseases to ensure that none of the 30 million people in Europe living with rare diseases are left behind by the start of a new decade. As part of…

The antibody rituximab is a good alternative to cyclophosphamide for inducing remission in people with ANCA-associated vasculitis (AAV), and is better than azathioprine as a maintenance therapy, researchers reported. These were among the findings from a recent review study that investigated the relative benefits and risks associated with different…

Use of avacopan can increase remission rates and improve kidney function in people with ANCA-associated vasculitis (AAV), while limiting the toxicity associated with standard steroid therapy, according to results from a Phase 3 clinical trial. Top-line data from the ADVOCATE trial, which opened on March 15, 2017, and concluded on…

The risk factors that predict serious infections in people with ANCA-associated vasculitis (AAV) vary with time, a study found. Factors associated with early infection include age and admission to an intensive care unit, whereas kidney function is the most important risk factor for late infections, the investigators said. The…

New statistical models could help to predict the risk of relapse and infection following ongoing rituximab treatment in people with ANCA-associated vasculitis (AAV), a study suggests. These models may aid in clinical decisions about the relative risks and benefits of continuing to use rituximab beyond its customary two years…

A survey is seeking people with ANCA-associated vasculitis (AAV) around the world to help researchers better understand how patients make decisions about treatment. Called OPTIONS Vasculitis, the survey is collecting responses from people with AAV, including granulomatosis with polyangiitis and microscopic polyangiitis, as…